Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Despite these positive outcomes, EyePoint's stock experienced a sharp decline. Cantor Fitzgerald analyst Jennifer Kim commented on the market reaction, stating, "There's nothing here that makes us ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

The MASAI trial reveals AI in mammography increases cancer detection by 29% and decreases radiologists' workload by 44%, ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Facing a breast cancer diagnosis, especially for individuals aged 60 and above, can be difficult. However, despite the ...

The biggest American Football match in the world will soon be taking place, but one competitor in the match has already ...

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...